NICE Pans Pomalidomide For Blood Cancer, Backs Xarelto In ACS Patients
This article was originally published in The Pink Sheet Daily
U.K. HTA rejects Celgene’s pomalidomide for treating multiple myeloma on cost grounds but waves through Bayer’s rivaroxaban for preventing blood clots in people who have had a heart attack.
You may also be interested in...
FDA approved the immunomodulator Feb. 8 for multiple myeloma patients who have failed at least two prior therapies, including lenalidomide and bortezomib.
Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.
Thalidomide and bortezomib could be recommended for in multiple myeloma, but NICE rejects Novartis' Xolair for children with severe allergic asthma.